Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tacit Therapeutics Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution landscape despite the small number of active matters. Each pending action is being reviewed in a different administrative environment, which requires the company to adapt to different sets of rules and technical expectations.
SARAH ELIZABETH ALLEN is identified as the busiest examiner for the company, holding 1 busiest examiner pending office action. This examiner handles a portion of the 2 pending office actions currently facing the company. The remaining workload is handled by the other of the 2 distinct examiners, spreading the tasks across the identified personnel. This distribution means that no single examiner has total control over the company's current patent outcomes.
The presence of 2 distinct art units suggests that the company's pending applications cover different technical sub-sectors within Biotechnology & Pharmaceuticals. With 2 distinct examiners involved, the company must manage different examination styles simultaneously. Resolving the 2 pending office actions will require distinct strategies for each examiner, including SARAH ELIZABETH ALLEN. The company should be prepared for potentially different timelines and requirements across the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, SARAH ELIZABETH | 1 | 56.7% | +33.3% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18485535 | HIGH EFFICIENCY TRANS-SPLICING FOR REPLACEMENT OF TARGETED RNA SEQUENCES IN HUMAN CELLS | ALLEN, SARAH ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18485535 | HIGH EFFICIENCY TRANS-SPLICING FOR REPLACEMENT OF TARGETED RNA SEQUENCES IN HUMAN CELLS | ALLEN, SARAH ELIZABETH | — |
| 18189896 | TRANS-SPLICING SYSTEM FOR TISSUE-SPECIFIC REPLACEMENT OF RNA SEQUENCES | DACE DENITO, ALEXANDRA GERALDINE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18485535 | HIGH EFFICIENCY TRANS-SPLICING FOR REPLACEMENT OF TARGETED RNA SEQUENCES IN HUMAN CELLS | ALLEN, SARAH ELIZABETH | 1637 | §101§102§103Other | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18189896 | TRANS-SPLICING SYSTEM FOR TISSUE-SPECIFIC REPLACEMENT OF RNA SEQUENCES | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §112DP | Non-Final OA | — | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTacit Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sarah Elizabeth Allen has the most, with 1 of Tacit Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
